生长抑素与洛赛克联合治疗重症急性胰腺炎的临床疗效

The Clinical Curative Effect of Somatostatin Combined with Losec in the Treatment of Severe Acute Pancreatitis

目的探讨生长抑素与洛赛克联合治疗重症急性胰腺炎(SAP)的临床疗效。方法选择我院重症急性胰腺炎的患者160例,随机分为两组,每组各80例:C组为对照组,不使用生长抑素与洛赛克;SO组除使用SAP常规治疗后,还联合应用生长抑素与洛赛克进行治疗。比较两组的治疗效果和治疗并发症。结果①SO组治疗总有效率(93.75%)明显高于C组(71.25%)(P<0.05)。SO组的肠道功能恢复时间、血和尿淀粉酶恢复正常时间、腹痛缓解时间、平均住院时间均比C组明显缩短(均P<0.05)。②SO组治疗后的胰腺假性囊肿、腹腔脓肿、肺部感染均比C组明显减少(均P<0.05);两组治疗后的死亡率无明显差异(P>0.05)。结论生长抑素与洛赛克联合治疗重症急性胰腺炎具有较好的疗效,值得临床推广。

Objective To study the efficacy of somatostatin ombined with losec in the treatment of severe acute pancreatitis （SAP）. Methods One hundred and sixty patients diagnozed with SAP were randomly divided into two groups, with 80 in each group： Group C （control group） was given routine treatment, and Group SO was given the somatostatin combined with losec besides the routine treatment. The clinical effect and the complications were recorded 7 days after the treatment duration. Results The recovery rate of the Group SO was 93.75% while the control group was only 71.25%. The alleviation time of abnormal pain and intestinal function recovery time, serum and urine amylase returned to normal time, and the clinical healing time were significant better than those in the control group （P 〈0.05）; the rates of pancreatic pseudocysts, peritoneal abscess and pulmonary infection in Group SO were all significantly lower than those in group C （P 〈0.05）. The mortality of the treatment had no significantly difference between the two groups. Conclusions The combination therapy of somatostatin and losec can increase clinical efficacy in patients with SAP.